A short summary of the current dilemma with antibiotic development. Others, including the World Health Organization and Infectious Diseases Society of America, have expressed this issue more elegantly and in greater detail (click on the links to check out), but it bears repeating: Drug discovery is tough. Discovering or creating a new (i.e. novel class of antibiotics) antibiotic […]

I have finally had the chance to read the Nature article (behind a pay wall) that has been making waves in the recent news, including the Guardian, Forbes and Bloomberg among others. The authors, who are from academic institutions in the USA (Boston) and Germany (Bonn), as well as a drug discovery company from the UK (Selcia, Ongar, […]